latanoprost (Xalatan)

1.	Stewart, William C: 14 articles (08/2008 - 08/2002)
2.	Stewart, W C: 9 articles (09/2008 - 06/2000)
3.	Konstas, Anastasios G P: 6 articles (10/2008 - 10/2004)
4.	Konstas, A G P: 4 articles (09/2008 - 01/2003)
5.	Stewart, Jeanette A: 4 articles (08/2008 - 03/2003)
6.	Parmeggiani, Francesco: 4 articles (03/2008 - 10/2003)
7.	Sebastiani, Adolfo: 4 articles (03/2008 - 10/2003)
8.	Costagliola, Ciro: 4 articles (03/2008 - 10/2003)
9.	Aung, Tin: 4 articles (10/2007 - 08/2002)
10.	Robin, Alan L: 4 articles (09/2006 - 01/2002)

Related Diseases

1.	Glaucoma 04/01/2000 - "These results suggest that latanoprost may be very effective in some patients with poorly controlled glaucoma on multiple therapy." 11/01/2002 - "The criterion for success was defined as having an IOP reduction of at least 20% from baseline or a final IOP of less than 22 mm Hg. Several clinical pretreatment variables (age, gender, ocular laterality, type of glaucoma, number of antiglaucomatous medications at study entry, pretreatment IOP) were analyzed for a significant effect on the efficacy of latanoprost additive therapy" 02/01/2001 - "These effects of latanoprost may be beneficial in the management of glaucoma patients." 03/01/2003 - "However, latanoprost was effective in only a minority of pediatric cases of glaucoma and is contraindicated in all forms of uveitic glaucoma" 03/01/2003 - "NTG: Latanoprost is effective in normal tension glaucoma (NTG), lowering IOP, improving pulsatile ocular blood flow and increasing ocular perfusion pressure" Get all the results and reference details, order at left...
2.	Ocular Hypertension (Glaucoma, Suspect) 01/01/2007 - "CONCLUSIONS: The study suggests that patients with ocular hypertension already treated with latanoprost monotherapy will continue to have, on average, at least midterm stable pressures, low incidence of side effects and discontinuations, as well as "very good" to "excellent" physician ratings of efficacy, tolerability, and patient satisfaction." 01/01/2007 - "RESULTS: 353 patients with ocular hypertension were included and treated with latanoprost monotherapy historically (1.4 +/- 1.3 years) and within the observational period of the study for a mean of 2.2 +/- 1.1 years" 01/01/2007 - "METHODS: A subanalysis of patients with ocular hypertension who were previously treated on latanoprost monotherapy and continued within the study on this same medication for at least 6 months" 09/01/1993 - "METHODS: In a randomized, double-masked, placebo-controlled study, PhXA41 (0.006%) was given topically twice daily for 1 week to one eye each of 22 volunteers with normotension or ocular hypertension" 04/01/1992 - "PhXA34, a prostaglandin analogue, was given topically to 40 patients with untreated ocular hypertension in a double masked randomised study" Get all the results and reference details, order at left...
3.	Open-Angle Glaucoma (Glaucoma, Open Angle) 11/01/2002 - "PURPOSE: To assess the efficacy of latanoprost as additive therapy in patients with open-angle glaucoma and an intraocular pressure (IOP) deemed to be too high on maximum tolerated medical therapy" 12/01/2003 - "CONCLUSION: Latanoprost monotherapy is a safe and effective alternative for many patients with open angle glaucoma requiring dual topical ocular hypotensive therapy for IOP control." 03/01/2008 - "First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study." 05/01/2002 - "Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma]" 03/01/2008 - "METHODS: This was a prospective, randomised, two-period crossover trial in ocular hypertensive or primary open-angle glaucoma patients (29 eyes in 15 patients) with an IOP of > 20 mmHg on latanoprost baseline treatment" Get all the results and reference details, order at left...
4.	Angle-Closure Glaucoma (Glaucoma, Angle Closure) 02/01/2005 - "The aim of this study was to evaluate the efficacy of 0.005% latanoprost in lowering intraocular pressure (IOP) in patients with chronic angle-closure glaucoma (CACG) and no visible ciliary-body face" 02/01/2005 - "Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study." 08/01/2002 - "Two independent, prospective trials were recently conducted to assess the efficacy of latanoprost in reducing intraocular pressure (IOP) in patients with primary angle-closure glaucoma (PACG)" 02/01/2005 - "OBJECTIVE: To examine the relationship between the configuration of the drainage angle and intraocular pressure (IOP)-lowering efficacy of latanoprost in subjects with chronic angle-closure glaucoma (CACG)" 08/01/2002 - "Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma." Get all the results and reference details, order at left...
5.	Herpetic Keratitis 11/01/2000 - "RESULTS/CONCLUSIONS: Episodes of herpetic keratitis were under remission only when latanoprost was discontinued" 05/01/1999 - "The third patient with latanoprost-associated herpes simplex keratitis cleared with the discontinuation of latanoprost and start of antiviral therapy; reinstitution of latanoprost with prophylactic antiviral medication kept the cornea clear, but as soon as the antiviral suppression was discontinued, herpes simplex keratitis reappeared" 03/01/2004 - "CONCLUSIONS: Herpetic keratitis may occur during treatment with latanoprost and beta-blockers" 06/01/2003 - "Our goal was to determine the effects of topical Xalatan and its components on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the Induced Reactivation (IR) and Spontaneous Shedding (SS) HSV-1/NZW rabbit latency models using virological outcome measures" 06/01/2003 - "PURPOSE: Xalatan treatment has been reported both clinically and experimentally to promote recurrences of herpetic keratitis" Get all the results and reference details, order at left...
88 Diseases and 593 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Timolol (Blocadren)
2.	bimatoprost (Lumigan)
3.	dorzolamide (Trusopt)
4.	travoprost (Travatan)
5.	latanoprost (Xalatan)
6.	brimonidine (Alphagan)
7.	Pilocarpine (Ocusert)
8.	Dinoprost
9.	hydroxide ion
10.	Carteolol (Carteolol Hydrochloride)
379 Drugs and Important Bio-Agents and 391 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Phacoemulsification
2.	Intraocular Lenses (Intraocular Lens)
3.	Aftercare (After-Treatment)
4.	Iridectomy
5.	Photorefractive Keratectomy
16 Therapies and Procedures and 37 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>